volume 5, issue 4, P432-447 2016
DOI: 10.21037/tcr.2016.06.20
View full text

Abstract: AbstractProstate cancer exhibits intra-tumoral heterogeneity that we hypothesize to be the leading confounding factor contributing to the underperformance of the current pre-treatment clinicalpathological and genomic assessment. These limitations impose an urgent need to develop better computational tools to identify men with low risk of prostate cancer versus others that may be at risk for developing metastatic cancer. The patient stratification will directly translate to patient treatments, wherein decision…

expand abstract